Executive Interviews

  1. What Makes Roche’s Approach To Partnering Unusual
    11/8/2017

    Sophie Kornowski-Bonnet, Roche’s head of partnering, also serves on the company’s senior leadership team — a rarity among top biopharma companies. But that’s not the only unusual fact about Roche’s approach to partnering.

  2. From Startup To Acquisition By Lilly, And Everything In Between
    11/8/2017

    “Going to medical school, completing my residency, and pursuing my Ph.D. were a cake walk in comparison to being the CEO of a biotech,” says Daniel Skovronsky, M.D., Ph.D., who talks about his journey from working out of his car to selling his company for $300 million and then going to work for Lilly.

  3. A Name Change — And More — For A Biotech
    10/10/2017

    When Maria Fardis, Ph.D., MBA, joined Lion Biotechnologies as CEO, she knew “The word ‘Lion’ didn’t really define us as a company or the advancements we had made with our TIL technology.” So, nine months into her tenure, Fardis and her team began the process of changing the company name to Iovance.

  4. Can David Hung Lead Axovant To Alzheimer’s Success?
    10/10/2017

    Why would David Hung, M.D., a veteran pharma executive, forgo retirement (after a big acquisition payday), join Axovant Sciences, and then invest $10 million of his own money into the small company? Our chief editor sat down with him to get the answers to those questions and more.

  5. Cytokinetics: Keeping Its Sights On Independence
    9/8/2017

    Can a biopharma company have a soul? If so, the soul should be one that endures. “The biology is the soul of our company,” says Robert Blum, president and CEO of Cytokinetics. “We have pioneered an area of biology — muscle activation — proven to offer a compelling pharmacology.

  6. Reaching A Turning Point With An Unusual Cancer Therapeutic
    9/8/2017

    Sometimes it pays to go against the grain. In 2013 Life Science Leader published an article describing the efforts of Dr. Ray Takigiku to establish Bexion Pharmaceuticals, a startup biotechnology firm, located in Covington, KY.

  7. Behind The Scenes Of Allergan’s Social Contract
    9/8/2017

    The story behind Allergan’s bold decision to formalize its social contract with patients told to our Chief Editor by Brent Saunders, Allergan’s chairman, president, and CEO.

  8. P3s: How To Get The Good …Without The Bad
    9/8/2017

    At this year’s BIO International Convention in San Diego (June 19 – 22), I moderated a session, Navigating A Clear Path To Public-Private Partnerships, and we talked about the good, the bad, and the ugly of P3s. After a brief introduction, the first question was posed, resulting in the following edited dialogue.

  9. Sanat Chattopadhyay — Shaping Merck’s Manufacturing Future
    8/9/2017

    It’s been a little over a year since Sanat Chattopadhyay was named president of Merck Manufacturing Division (MMD), and this month he gives an exclusive interview on the status of the division’s transformational turnaround.

  10. Chasing Invention: Jeffrey Kindler At The Helm Of Centrexion
    8/9/2017

    As former chairman and CEO of Pfizer, Jeffrey Kindler dealt with the frustrating conundrum of ballooning R&D budgets tracking alongside plunging R&D productivity. Now as he leads this chronic pain biopharma startup, he has a whole new set of challenges.